慢性阻塞性肺疾病患者使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂时脓毒症与死亡风险
该回顾性研究基于台湾全民健康保险研究数据库,纳入2000至2005年间接受ACEI或ARB治疗超过90天的COPD患者,经1:1配对后ACEI组和ARB组各5959例。主要终点为脓毒症,次要终点为死亡。ACEI组脓毒症发生率为3.67/100人年,ARB组为2.87/100人年;ACEI组感染性休克风险(aHR 1.45,95%CI 1.26-1.67)和死亡风险(aHR 1.31,95%CI 1.22-1.40)均高于ARB组。无论患者索引日前是否发生过严重急性加重,ACEI组脓毒症、感染性休克和死亡风险均高于ARB组(均p<0.001)。结论认为在COPD患者中ARB与较低的脓毒症和死亡发生率相关,亚组分析结果相似。
要点
- 在COPD患者中,ACEI组脓毒症发生率为3.67/100人年,ARB组为2.87/100人年。
- ACEI组感染性休克风险高于ARB组:aHR 1.45(95%CI 1.26-1.67)。
- ACEI组死亡风险高于ARB组:aHR 1.31(95%CI 1.22-1.40)。
- 无论索引日前是否有严重急性加重,ACEI组脓毒症、感染性休克和死亡风险均高于ARB组(均p<0.001)。
- 该研究为回顾性研究,基于台湾全民健康保险研究数据库,ACEI组和ARB组各5959例。
适用人群与场景
- 2000至2005年间接受ACEI或ARB治疗超过90天的COPD患者,来自台湾全民健康保险研究数据库。
- 经1:1配对后ACEI组和ARB组各5959例。
研究设计与关键结果
- 研究类型:回顾性研究,基于台湾全民健康保险研究数据库;ACEI组与ARB组经1:1配对后各5959例。
- 主要终点脓毒症发生率:ACEI组3.67/100人年 vs ARB组2.87/100人年。
- 感染性休克风险:ACEI组高于ARB组,aHR 1.45(95%CI 1.26-1.67)。
- 死亡风险:ACEI组高于ARB组,aHR 1.31(95%CI 1.22-1.40)。
- 亚组分析:无论索引日前是否有严重急性加重,ACEI组脓毒症、感染性休克和死亡风险均高于ARB组(均p<0.001)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在COPD患者中,使用ARB与较低的脓毒症和死亡发生率相关,使用ACEI者脓毒症、感染性休克和死亡风险较高。
- 该结论来自回顾性研究,原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to compare the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk and outcomes of sepsis in patients with chronic obstructive pulmonary disease.
DESIGN: A retrospective study.
SETTING: Taiwan's National Health Insurance Research Database.
PATIENTS: All patients with chronic obstructive pulmonary disease who received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for more than 90 days between 2000 and 2005 were recruited for this study. Pairwise matching (1:1) of the angiotensin-converting enzyme inhibitor and angiotensin receptor blocker groups resulted in two similar subgroups with 5,959 patients in each.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was sepsis, and the secondary outcome was death. The occurrence rate of sepsis was 3.67 per 100 person-years for the patients receiving angiotensin-converting enzyme inhibitors and 2.87 per 100 person-years for those receiving angiotensin receptor blockers. In addition, the patients receiving angiotensin-converting enzyme inhibitors had a higher risk of septic shock (adjusted hazard ratio, 1.45; 95% CI, 1.26-1.67) and mortality (adjusted hazard ratio, 1.31; 95% CI, 1.22-1.40) than those receiving angiotensin receptor blockers. No matter whether the patients had prior severe exacerbation before the index date, those receiving angiotensin-converting enzyme inhibitors had a higher risk of sepsis, septic shock, and mortality than those receiving angiotensin receptor blockers (all p < 0.001).
CONCLUSIONS: Angiotensin receptor blockers were associated with lower rates of sepsis and mortality than angiotensin-converting enzyme inhibitors in the patients with chronic obstructive pulmonary disease. The similar findings were also noted in subgroup analysis.
参考来源
- Lai CC, Wang YH, Wang CY, et al. Risk of Sepsis and Mortality Among Patients With Chronic Obstructive Pulmonary Disease Treated With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. Crit Care Med. 2019. PMID: 30303835. doi:10.1097/CCM.0000000000003475
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。